Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic InSync ICD Panel Review Anticipated, SCD-HeFT Payoff Awaited

This article was originally published in The Gray Sheet

Executive Summary

Medtronic expects its InSync ICD combination resynchronization/ICD premarket approval application to go before FDA's Circulatory System Devices Panel in March 2002

You may also be interested in...

Medtronic Tops Charts With InSync FDA Approval Ahead Of Schedule

Medtronic will be allowed to use patients enrolled in the trials of its next-generation InSync III to partially fulfill a 1,000-patient, post-approval study requirement for the current generation InSync biventricular pacing system for congestive heart failure, FDA says.

Medtronic InSync Panel OK May Presage September FDA Approval

The Circulatory System Devices Panel's approvable recommendation for Medtronic's InSync pacing system sets the stage for FDA final sign-off by Sept. 30, the last day of the federal fiscal year.

Favorable SCD-HeFT/MADIT II Results Would Boost Prophylactic ICD Use

Positive results from two ongoing clinical trials currently examining implantable cardioverter defibrillators (ICDs) in preventing sudden cardiac death could lead to "a tremendous increase in prophylactic use," Gust Bardy, MD, University of Washington, Seattle predicted May 17.

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts